The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The requested target is unambiguous: human MAPK14 encodes mitogen-activated protein kinase 14, p38α/SAPK2a, corresponding to canonical UniProt Q16539-1. It is not MAPK11/p38β, MAPK12/p38γ, or MAPK13/p38δ. The reported 360-amino-acid, approximately 41.3-kDa protein and its kinase domain, ATP-binding architecture, and Thr-Gly-Tyr activation loop agree with the supplied CMGC Ser/Thr kinase, MAPK, MAPK14, and HOG-like domain annotations. No evidence concerning a similarly named gene in another organism was used. (moralesmartinez2024p38moleculartargeting pages 2-4, canovas2021diversityandversatility pages 1-2)
MAPK14 is best annotated as a stress- and inflammation-responsive, proline-directed protein serine/threonine kinase. Its primary biochemical function is ATP-dependent phosphorylation of Ser/Thr residues—preferentially Ser/Thr-Pro sites—in proteins selected not merely by the local phosphoacceptor sequence but also by docking interactions, scaffolds, localization, and stimulus context. Canonical activation is by MKK3/MKK6-mediated dual phosphorylation of Thr180 and Tyr182; TAB1-dependent autophosphorylation and T-cell-receptor–ZAP70 signaling provide alternative activation routes. Activated p38α acts in the cytosol and nucleus, principally through MK2/MK3, MSK1/2, MNK1/2, transcriptional and chromatin regulators, and proteins controlling RNA turnover and the cytoskeleton. (canovas2021diversityandversatility pages 2-3, canovas2021diversityandversatility pages 5-5, canovas2021diversityandversatility pages 1-2, dan2023characterizationofp38α pages 1-4)
| Aspect | Best-supported annotation | Evidence type / key quantitative detail | Main source(s), year, DOI URL |
|---|---|---|---|
| Identity | Human MAPK14 encodes p38α/SAPK2a, corresponding to canonical UniProt Q16539-1; it is distinct from MAPK11/p38β, MAPK12/p38γ, and MAPK13/p38δ. | Direct nomenclature and database concordance; 360 aa, approximately 41.3 kDa; gene at 6p21.31. | Morales-Martínez & Vega, 2024, DOI (moralesmartinez2024p38moleculartargeting pages 2-4); Canovas & Nebreda, 2021, DOI (canovas2021diversityandversatility pages 1-2) |
| Catalytic reaction and substrate preference | ATP-dependent transfer of the γ-phosphate to protein serine or threonine: ATP + protein-OH → ADP + phosphoprotein. MAPK14 is a proline-directed Ser/Thr kinase favoring Ser/Thr-Pro sites, but docking interactions are major determinants of physiological specificity. | Kinase-family and biochemical evidence; more than 100 direct p38α substrates have been reported, although screening-derived candidates require direct phosphorylation validation. | Canovas & Nebreda, 2021, DOI (canovas2021diversityandversatility pages 1-2, canovas2021diversityandversatility pages 5-5); Dan et al., 2023 preprint, DOI (dan2023characterizationofp38α pages 1-4) |
| Structure and domains | A bilobal CMGC/MAPK kinase consistent with the supplied kinase-like, MAPK, MAPK14, and HOG-like annotations. The kinase domain spans approximately residues 24–308; ATP binds in the interlobe cleft, and the activation loop contains Thr180-Gly-Tyr182. | Structural annotation: N-lobe residues 1–105, hinge 106–113, and C-lobe 114–316; ATP-site-associated residues include Lys53, Arg67, Arg70, Glu71, and Asp168. | Morales-Martínez & Vega, 2024, DOI (moralesmartinez2024p38moleculartargeting pages 2-4); Canovas & Nebreda, 2021, DOI (canovas2021diversityandversatility pages 5-5) |
| Canonical activation | Stress, inflammatory, and innate-immune inputs engage MAP3K→MAP2K cascades. MKK3/MAP2K3 and MKK6/MAP2K6, and contextually MKK4/MAP2K4, activate p38α by phosphorylating Thr180 and Tyr182. | Biochemical, genetic, and structural evidence; dual phosphorylation reorganizes the activation loop and ATP/Mg²⁺ environment. Up to approximately 10 MAP3Ks can contribute depending on stimulus and cell type. | Canovas & Nebreda, 2021, DOI (canovas2021diversityandversatility pages 2-3, canovas2021diversityandversatility pages 5-5); Juyoux et al., 2023, DOI (juyoux2023architectureofthe pages 1-3) |
| Atypical activation | TAB1 binding can induce MAP2K-independent p38α autophosphorylation. In T cells, TCR–ZAP70 signaling phosphorylates Tyr323, promoting preferential Thr180 autophosphorylation. Endosomal GPCR–TAB1/TAB2 complexes provide spatially restricted atypical activation. | Mechanistic biochemical and cell-signaling evidence; TAB1-mediated activation is relatively selective for p38α. | Canovas & Nebreda, 2021, DOI (canovas2021diversityandversatility pages 2-3); Burton et al., 2021, DOI (burton2021atypicalp38signaling pages 4-5, burton2021atypicalp38signaling pages 2-4) |
| Signal termination | MAPK14 is inactivated by removal of one or both activation-loop phosphates. Regulators include DUSP1/MKP1, DUSP10/MKP5, DUSP16, DUSP26/MKP8, DUSP12, and PPM1D/Wip1; DUSP1 participates in negative feedback. | Phosphatase specificity and perturbation evidence; contributions vary by cell type and stimulus. | Morales-Martínez & Vega, 2024, DOI (moralesmartinez2024p38moleculartargeting pages 2-4); Burton et al., 2021, DOI (burton2021atypicalp38signaling pages 4-5) |
| Localization | p38α functions in both cytosol and nucleus. Cytosolic outputs include kinase, RNA-regulatory, and cytoskeletal modules; activated p38α can enter the nucleus to phosphorylate transcriptional and chromatin regulators. Complex formation with MK2 helps coordinate nuclear–cytoplasmic trafficking. | Cellular localization and interaction evidence; localization is dynamic and depends on stimulus, scaffold, and substrate. | Morales-Martínez & Vega, 2024, DOI (moralesmartinez2024p38moleculartargeting pages 2-4); Juyoux et al., 2023, DOI (juyoux2023architectureofthe pages 1-3) |
| Principal direct substrates and output modules | Major direct substrates include MK2/MAPKAPK2, MK3/MAPKAPK3, MSK1/2, and MNK1/2. The p38α–MK2 axis controls HSP27-dependent cytoskeletal remodeling and post-transcriptional regulation through TTP and HuR; MSKs connect signaling to CREB, histone H3, and other nuclear targets. | Direct phosphorylation and pathway evidence. Cytokines and many phosphoproteomic hits are downstream outputs, not necessarily direct MAPK14 substrates. | Canovas & Nebreda, 2021, DOI (canovas2021diversityandversatility pages 5-5); Burton et al., 2021, DOI (burton2021atypicalp38signaling pages 4-5) |
| 2023 structural advance | The first integrative structure of an activation-competent MKK6–p38α complex revealed a face-to-face kinase arrangement, a C-lobe-dominated interface, engagement of the MAPK-specific insert, and extension of the p38α activation loop toward the MKK6 active site. | Cryo-EM, HDX-MS, SAXS, molecular dynamics, and cellular experiments; approximately 80-kDa engineered complex at nominal 4 Å resolution, with 2.7–6.5 Å local resolution. A GRA24-derived KIM reportedly bound p38α about 100-fold more strongly than the native MKK6 KIM. | Juyoux et al., 2023, DOI (juyoux2023architectureofthe pages 3-4) |
| 2023 phosphoproteomics | In proliferating breast-cancer cells, genetic MAPK14 loss and selective inhibition implicated p38α in cell adhesion, DNA replication, and RNA metabolism, including ArgBP2-linked negative regulation of adhesion. | Quantitative proteomics identified 35 proteins, 82 phosphoproteins, and 114 phosphosites modulated by p38α. Not all are direct substrates, and the report was a preprint. | Dan et al., 2023 preprint, DOI (dan2023characterizationofp38α pages 1-4) |
| 2024 FSHD finding | Combined MAPK14/MAPK11 deletion or p38α/β inhibition reduced early differentiation-associated DUX4 expression in patient-derived FSHD muscle cells, but later DUX4 induction became partly p38-independent. Losmapimod did not suppress late xenograft DUX4-target expression. This is p38α/β evidence, not MAPK14-specific evidence. | CRISPR, pharmacological, patient-derived cell, and xenograft evidence. A prior phase IIb losmapimod trial missed its primary DUX4-target-expression endpoint despite improvements in secondary functional outcomes. | Vangipurapu et al., 2024, DOI (vangipurapu2024temporalvariationin pages 1-2) |
| Translational status and limitations | MAPK14 is druggable, and p38 inhibitors have entered studies in inflammatory, pulmonary, neurological, muscular, and oncological disorders, but broad clinical success has not been established. Key limitations are adaptive compensation, toxicity and off-target activity, ATP-site conservation, context-dependent biology, and failure to distinguish p38α from p38β. | Clinical and preclinical synthesis. SB203580 and losmapimod inhibit p38α/β rather than MAPK14 alone; ralimetinib is broader. New approaches target docking surfaces, the p38α–TAB1 interface, downstream MK2, or compartment-specific signaling. | Burton et al., 2021, DOI (burton2021atypicalp38signaling pages 4-5, burton2021atypicalp38signaling pages 5-6); García-Hernández et al., 2021, DOI (garciahernandez2021thep38mapk pages 13-14) |
Table: Concise evidence table verifying human MAPK14/Q16539 and summarizing its enzymatic function, regulation, localization, downstream modules, recent mechanistic advances, and translational limitations. It explicitly separates MAPK14-specific findings from combined p38α/β or pan-p38 evidence.
MAPK14 is located at 6p21.31 and encodes p38α, also called SAPK2a, CSBP, or CSAID-binding protein. The canonical product comprises 360 amino acids and has a reported molecular mass of 41,293 Da; its protein-kinase domain spans approximately residues 24–308. Alternative transcripts exist, so isoform-specific observations should not automatically be assigned to the canonical protein. (moralesmartinez2024p38mapkmolecular pages 2-4, moralesmartinez2024p38moleculartargeting pages 2-4)
The protein has the expected bilobal kinase fold: an N-terminal lobe, flexible hinge, and larger C-terminal lobe containing the catalytic and activation segments. Structural descriptions place the N-lobe at residues 1–105, hinge at 106–113, and C-lobe at 114–316; ATP-site-associated residues include Lys53, Arg67, Arg70, Glu71, and catalytic-region Asp168. The activation segment contains Thr180-Gly181-Tyr182, whose dual phosphorylation produces the fully active conformation. These features strongly corroborate the supplied InterPro kinase-like, MAP kinase, MAPK14, and HOG-like domain assignments. (canovas2021diversityandversatility pages 5-5)
The net reaction is:
ATP + protein–Ser/Thr–OH → ADP + protein–Ser/Thr–OPO₃²⁻ + H⁺.
As a MAP kinase, p38α is proline directed, preferentially phosphorylating Ser/Thr followed by proline. This short motif is insufficient to explain biological specificity: kinase-interaction or docking motifs on substrates and regulators bind complementary p38α docking surfaces, increasing local affinity and correctly orienting the phosphoacceptor. Substrate docking cooperates with ATP loading, substrate engagement, and phosphotransfer. Consequently, a phosphoproteomic Ser/Thr-Pro site that changes after MAPK14 perturbation is a candidate pathway output, not automatically a direct MAPK14 substrate. (canovas2021diversityandversatility pages 5-5, dan2023characterizationofp38α pages 1-4)
More than 100 direct p38α substrates have been reported, but confidence varies. The most established proximal substrates include MAPKAPK2/MK2, MAPKAPK3/MK3, MSK1/2, and MNK1/2. Downstream of p38α–MK2, HSP27 regulates actin remodeling, while tristetraprolin/TTP and HuR alter inflammatory-mRNA stability and translation. MSK enzymes connect the pathway to CREB, histone H3, and other nuclear targets. Cytokines such as TNF, IL-1, IL-6, and IL-8 are important pathway inputs or outputs but should not be mislabeled as direct kinase substrates. (burton2021atypicalp38signaling pages 4-5, canovas2021diversityandversatility pages 5-5)
Environmental or intracellular stress—including osmotic and oxidative stress, irradiation, hypoxia, DNA damage, infection, and inflammatory cytokines—activates MAP3Ks such as TAK1, ASK1, MEKK-family kinases, or MLK3. These activate MKK3/MAP2K3 and MKK6/MAP2K6, with MKK4 contributing in some contexts. MKK3/6 then phosphorylate MAPK14 at both Thr180 and Tyr182. The participating MAP3K and MAP2K vary with cell type, stimulus, and scaffold, explaining why “p38 activation” does not imply an invariant biological response. (machado2021thep38mapk pages 1-2, canovas2021diversityandversatility pages 2-3, burton2021atypicalp38signaling pages 2-4)
A major 2023 structural advance resolved an activation-competent MKK6–p38α assembly by integrating cryo-EM, HDX-MS, SAXS, molecular dynamics, and cellular experiments. The approximately 80-kDa complex was reconstructed at nominal 4-Å resolution with local resolution of 2.7–6.5 Å. It adopts a face-to-face orientation dominated by C-lobe contacts, with the p38α activation loop extending toward the MKK6 active site. Because the native interaction is transient, the researchers used an engineered GRA24-derived kinase-interaction motif reported to bind p38α approximately 100-fold more strongly than native MKK6; this stabilization is informative but should be remembered when interpreting the structure as a native-state model. (juyoux2023architectureofthe pages 3-4)
TAB1 binding can induce MAP2K-independent p38α autophosphorylation, an atypical route studied in ischemia, inflammation, GPCR signaling, and other pathological stresses. In T cells, TCR-activated ZAP70 phosphorylates p38α Tyr323, promoting preferential Thr180 autophosphorylation and potentially changing substrate preference. Ubiquitinated GPCRs can also assemble TAB1/TAB2-containing endosomal complexes, providing spatially localized p38α activation. (canovas2021diversityandversatility pages 2-3, burton2021atypicalp38signaling pages 2-4, burton2021atypicalp38signaling pages 4-5)
Activity ends when activation-loop phosphates are removed. Relevant regulators include DUSP1/MKP1, DUSP10/MKP5, DUSP16, DUSP26/MKP8, DUSP12, and PPM1D/Wip1, although specificity and importance are context dependent. DUSP1 participates in negative feedback, while p38α can itself regulate components such as MKK6, TAB1, and ZAP70. Acetylation also modifies activity: Lys53 acetylation has been associated with increased ATP affinity and catalytic activity. (moralesmartinez2024p38mapkmolecular pages 2-4, moralesmartinez2024p38moleculartargeting pages 2-4, burton2021atypicalp38signaling pages 4-5, canovas2021diversityandversatility pages 2-3)
MAPK14 is a soluble intracellular kinase operating in both cytosol and nucleus, rather than a secreted or transmembrane protein. Cytosolic p38α phosphorylates kinase modules, RNA-regulatory proteins, metabolic and endocytic proteins, and cytoskeletal regulators. After activation, a fraction enters the nucleus, where it influences transcription factors, chromatin proteins, and gene expression. The p38α–MK2 complex helps coordinate compartmental trafficking, while scaffolds can retain signaling at specialized sites such as endosomes. (burton2021atypicalp38signaling pages 4-5, moralesmartinez2024p38moleculartargeting pages 2-4, juyoux2023architectureofthe pages 1-3)
Localization should therefore be annotated as dynamic rather than as a single compartment. An authoritative assessment identifies unresolved questions about how canonical MKK3/6 activation versus atypical TAB1-dependent activation changes p38α localization and substrate access; compartment-specific signaling remains an important research gap. (burton2021atypicalp38signaling pages 4-5, burton2021atypicalp38signaling pages 5-6)
The most precise pathway description is:
Stress/inflammatory receptor → context-specific MAP3K → MKK3/MKK6 → MAPK14/p38α → MK2/MK3, MSK1/2, MNK1/2 and direct nuclear/cytosolic substrates → adaptive changes in transcription, chromatin, mRNA stability, translation, cytoskeleton, metabolism, cell cycle, and survival.
This architecture enables p38α to translate diverse stress inputs into temporally and spatially appropriate responses. Its functions include innate-inflammatory signaling, stress adaptation, differentiation, tissue homeostasis, DNA-damage responses, and regulation of apoptosis or survival. Outcomes can be opposite in different cells—for example, growth arrest versus survival—because substrate abundance, pathway duration, localization, and cross-talk differ. The 2021 Nature Reviews analysis accordingly treats p38α as a context-dependent signaling hub rather than simply a universal “pro-inflammatory kinase.” (canovas2021diversityandversatility pages 5-5, canovas2021diversityandversatility pages 1-2)
A 2023 breast-cancer-cell study combined genetic MAPK14 deletion with the p38α-selective inhibitor PH-797804. It identified 35 proteins, 82 phosphoproteins, and 114 phosphosites modulated by p38α and implicated MK2 and mTOR-linked networks, cell adhesion, DNA replication, and RNA metabolism. Functional experiments supported p38α-dependent negative regulation of adhesion involving ArgBP2. However, the report was a preprint, was performed in a particular cancer-cell context, and did not establish every altered phosphosite as a direct MAPK14 substrate. (dan2023characterizationofp38α pages 1-4)
A November 2024 study used combined MAPK14/MAPK11 deletion and pharmacological p38α/β inhibition in FSHD patient-derived muscle cells. p38α/β activity was important for early differentiation-associated DUX4 induction, but later DUX4 and DUX4-target expression became partly p38 independent; losmapimod also failed to suppress late target-gene expression in xenografts. This helps explain why a phase IIb trial improved some secondary functional outcomes yet missed its primary DUX4-target-expression endpoint. Importantly, this is combined p38α/β evidence and cannot be assigned exclusively to MAPK14. (vangipurapu2024temporalvariationin pages 1-2)
Open Targets links MAPK14 to neurodegenerative and neuroinflammatory phenotypes using functional-genomics evidence, including CRISPR screens in induced astrocytes, microglia, and neurons. Its reported association scores include approximately 0.337 for Alzheimer disease, 0.316 for Parkinson disease, 0.306 for multiple sclerosis, and 0.530 for the broader neurodegenerative-disease category. These are evidence-integration scores, not effect sizes or proof that MAPK14 inhibition will benefit patients. (OpenTargets Search: -MAPK14)
MAPK14/p38α is tractable with small molecules, and p38-directed agents have reached trials in inflammatory disease, pulmonary disease, cancer, Alzheimer disease, and muscular disorders. Representative programs include neflamapimod in Alzheimer disease, losmapimod in FSHD and cardiovascular settings, ralimetinib in oncology, and PH-797804 or related inhibitors in inflammatory indications. Preclinical studies also use MAPK14 inhibition to sensitize tumors to chemotherapy or alter inflammatory and stromal signaling. (garciahernandez2021thep38mapk pages 13-14, burton2021atypicalp38signaling pages 5-6)
Nevertheless, there is no broadly established MAPK14-targeted standard therapy. Early ATP-pocket inhibitors often inhibit both p38α and p38β; SB203580, for example, is not MAPK14 specific and also has relevant off-target pharmacology. Chronic efficacy has frequently been transient, plausibly because compensatory inflammatory pathways emerge, while pathway ubiquity creates toxicity and on-target physiological liabilities. Trial interpretation is further complicated when compounds are described generically as “p38 inhibitors” without rigorous isoform selectivity. (canovas2021diversityandversatility pages 5-5, burton2021atypicalp38signaling pages 4-5, burton2021atypicalp38signaling pages 5-6)
Current drug-development strategies therefore increasingly emphasize:
The docking-site ligand UM101 illustrates this logic: it was designed to preserve anti-inflammatory MSK1 signaling while suppressing selected pathological outputs in mouse acute-lung-injury models. Such approaches remain predominantly preclinical. (burton2021atypicalp38signaling pages 5-6)
High-confidence annotation: MAPK14/Q16539 is human p38α, a cytosolic/nuclear, ATP-dependent, proline-directed Ser/Thr MAP kinase activated primarily through MKK3/MKK6 phosphorylation of Thr180/Tyr182. MK2/MK3, MSK1/2, and MNK1/2 are established proximal substrates or output modules. (moralesmartinez2024p38moleculartargeting pages 2-4, canovas2021diversityandversatility pages 2-3, canovas2021diversityandversatility pages 1-2)
Moderate-confidence/context-dependent annotation: individual disease roles, additional direct substrates, and compartment-specific functions. These often depend on cell type, stimulus duration, and experimental model and may derive from inhibitor-sensitive phosphoproteomics rather than direct in-vitro phosphorylation. (dan2023characterizationofp38α pages 1-4, canovas2021diversityandversatility pages 5-5)
Key caveat: “p38,” phospho-p38 antibodies, and many inhibitors do not distinguish MAPK14/p38α from p38β or other family members. Claims should be considered MAPK14 specific only when supported by isoform-selective genetics, validated selective inhibitors, or direct biochemical assays. This distinction is particularly important for FSHD and many clinical studies. (vangipurapu2024temporalvariationin pages 1-2, canovas2021diversityandversatility pages 5-5)
MAPK14 encodes the principal human p38α stress kinase. Its primary function is docking-assisted phosphorylation of proline-directed Ser/Thr sites in cytosolic and nuclear proteins following canonical MKK3/6-dependent or specialized atypical activation. The resulting MK2/MK3, MSK, MNK, transcriptional, RNA-regulatory, and cytoskeletal outputs coordinate adaptation to stress and inflammation. The 2023 MKK6–p38α structure substantially improved mechanistic understanding of dual phosphorylation, while recent phosphoproteomic and disease-model studies demonstrate that MAPK14 output is highly context and time dependent. Therapeutic relevance is substantial, but clinical translation remains constrained by isoform ambiguity, adaptive compensation, off-target effects, and the physiological breadth of p38α signaling.
References
(moralesmartinez2024p38moleculartargeting pages 2-4): Mario Morales-Martínez and Mario I. Vega. P38 molecular targeting for next-generation multiple myeloma therapy. Cancers, 16:256, Jan 2024. URL: https://doi.org/10.3390/cancers16020256, doi:10.3390/cancers16020256. This article has 8 citations.
(canovas2021diversityandversatility pages 1-2): Begoña Canovas and Angel R. Nebreda. Diversity and versatility of p38 kinase signalling in health and disease. Nature Reviews. Molecular Cell Biology, 22:346-366, Jan 2021. URL: https://doi.org/10.1038/s41580-020-00322-w, doi:10.1038/s41580-020-00322-w. This article has 789 citations.
(canovas2021diversityandversatility pages 2-3): Begoña Canovas and Angel R. Nebreda. Diversity and versatility of p38 kinase signalling in health and disease. Nature Reviews. Molecular Cell Biology, 22:346-366, Jan 2021. URL: https://doi.org/10.1038/s41580-020-00322-w, doi:10.1038/s41580-020-00322-w. This article has 789 citations.
(canovas2021diversityandversatility pages 5-5): Begoña Canovas and Angel R. Nebreda. Diversity and versatility of p38 kinase signalling in health and disease. Nature Reviews. Molecular Cell Biology, 22:346-366, Jan 2021. URL: https://doi.org/10.1038/s41580-020-00322-w, doi:10.1038/s41580-020-00322-w. This article has 789 citations.
(dan2023characterizationofp38α pages 1-4): Yuzhen Dan, Nevenka Radic, Marina Gay, Adrià Fernández-Torras, Gianluca Arauz, Marta Vilaseca, Patrick Aloy, Begoña Canovas, and Angel R. Nebreda. Characterization of p38α signaling networks in cancer cells using quantitative proteomics and phosphoproteomics. bioRxiv, Sep 2023. URL: https://doi.org/10.1101/2022.09.09.507259, doi:10.1101/2022.09.09.507259. This article has 12 citations.
(juyoux2023architectureofthe pages 1-3): Pauline Juyoux, Ioannis Galdadas, Dorothea Gobbo, Jill von Velsen, Martin Pelosse, Mark Tully, Oscar Vadas, Francesco Luigi Gervasio, Erika Pellegrini, and Matthew W. Bowler. Architecture of the mkk6-p38α complex defines the basis of mapk specificity and activation. Science, 381:1217-1225, Sep 2023. URL: https://doi.org/10.1126/science.add7859, doi:10.1126/science.add7859. This article has 58 citations and is from a highest quality peer-reviewed journal.
(burton2021atypicalp38signaling pages 4-5): Jeremy C. Burton, William Antoniades, Jennifer Okalova, Morgan M. Roos, and Neil J. Grimsey. Atypical p38 signaling, activation, and implications for disease. International Journal of Molecular Sciences, 22:4183, Apr 2021. URL: https://doi.org/10.3390/ijms22084183, doi:10.3390/ijms22084183. This article has 81 citations.
(burton2021atypicalp38signaling pages 2-4): Jeremy C. Burton, William Antoniades, Jennifer Okalova, Morgan M. Roos, and Neil J. Grimsey. Atypical p38 signaling, activation, and implications for disease. International Journal of Molecular Sciences, 22:4183, Apr 2021. URL: https://doi.org/10.3390/ijms22084183, doi:10.3390/ijms22084183. This article has 81 citations.
(juyoux2023architectureofthe pages 3-4): Pauline Juyoux, Ioannis Galdadas, Dorothea Gobbo, Jill von Velsen, Martin Pelosse, Mark Tully, Oscar Vadas, Francesco Luigi Gervasio, Erika Pellegrini, and Matthew W. Bowler. Architecture of the mkk6-p38α complex defines the basis of mapk specificity and activation. Science, 381:1217-1225, Sep 2023. URL: https://doi.org/10.1126/science.add7859, doi:10.1126/science.add7859. This article has 58 citations and is from a highest quality peer-reviewed journal.
(vangipurapu2024temporalvariationin pages 1-2): Rajanikanth Vangipurapu, Jonathan Oliva, Amelia Fox, and Francis M. Sverdrup. Temporal variation in p38-mediated regulation of dux4 in facioscapulohumeral muscular dystrophy. Scientific Reports, Nov 2024. URL: https://doi.org/10.1038/s41598-024-77911-8, doi:10.1038/s41598-024-77911-8. This article has 12 citations and is from a peer-reviewed journal.
(burton2021atypicalp38signaling pages 5-6): Jeremy C. Burton, William Antoniades, Jennifer Okalova, Morgan M. Roos, and Neil J. Grimsey. Atypical p38 signaling, activation, and implications for disease. International Journal of Molecular Sciences, 22:4183, Apr 2021. URL: https://doi.org/10.3390/ijms22084183, doi:10.3390/ijms22084183. This article has 81 citations.
(garciahernandez2021thep38mapk pages 13-14): Laura García-Hernández, María Belén García-Ortega, Gloria Ruiz-Alcalá, Esmeralda Carrillo, Juan Antonio Marchal, and María Ángel García. The p38 mapk components and modulators as biomarkers and molecular targets in cancer. International Journal of Molecular Sciences, 23:370, Dec 2021. URL: https://doi.org/10.3390/ijms23010370, doi:10.3390/ijms23010370. This article has 132 citations.
(moralesmartinez2024p38mapkmolecular pages 2-4): Mario Morales-Martinez and Mario I Vega. P38 mapk molecular targeting for next-generation multiple myeloma therapy. Unknown journal, Jan 2024. URL: https://doi.org/10.20944/preprints202401.0262.v1, doi:10.20944/preprints202401.0262.v1.
(machado2021thep38mapk pages 1-2): Thamires R. Machado, Thayná R. Machado, and Pedro G. Pascutti. The p38 mapk inhibitors and their role in inflammatory diseases. ArXiv, 6:5729-5742, Jun 2021. URL: https://doi.org/10.1002/slct.202100406, doi:10.1002/slct.202100406. This article has 49 citations.
(OpenTargets Search: -MAPK14): Open Targets Query (-MAPK14, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.